HC Wainwright Analysts Lower Earnings Estimates for Precigen

Key Points

• HC Wainwright revised its Q3 2025 earnings estimate for Precigen, projecting a loss of ($0.09) per share, down from the previous estimate of ($0.07).
• Despite the negative outlook, HC Wainwright maintains a "Buy" rating for Precigen with a target price of $6.00.
• Precigen's most recent earnings report showed a loss of ($0.11) per share, which was better than analysts' expectations of ($0.14) per share.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Precigen in a report issued on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.07). HC Wainwright currently has a "Buy" rating and a $8.50 price target on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.06) EPS.

A number of other brokerages have also recently weighed in on PGEN. Citigroup restated an "outperform" rating on shares of Precigen in a report on Tuesday. JMP Securities lifted their price objective on Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. Wall Street Zen upgraded shares of Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Finally, JPMorgan Chase & Co. upgraded shares of Precigen from an "underweight" rating to a "neutral" rating in a report on Friday, August 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $8.25.

Precigen Stock Down 2.3%

NASDAQ PGEN traded down $0.0750 during trading on Friday, hitting $3.1450. The stock had a trading volume of 5,017,398 shares, compared to its average volume of 3,350,448. The company has a market capitalization of $937.12 million, a PE ratio of -7.49 and a beta of 1.87. The firm has a 50 day moving average price of $1.74 and a 200 day moving average price of $1.62. Precigen has a twelve month low of $0.65 and a twelve month high of $3.49.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.67 million.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently made changes to their positions in PGEN. Envestnet Asset Management Inc. boosted its position in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares during the period. Invesco Ltd. increased its position in Precigen by 14.6% during the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock worth $53,000 after buying an additional 6,040 shares during the period. Rhumbline Advisers lifted its stake in Precigen by 3.7% in the second quarter. Rhumbline Advisers now owns 198,078 shares of the biotechnology company's stock valued at $281,000 after buying an additional 7,041 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock valued at $122,000 after acquiring an additional 9,043 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Precigen by 26.6% in the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after acquiring an additional 10,900 shares during the period. Institutional investors and hedge funds own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.